Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 2:8:160.
doi: 10.3389/fcell.2020.00160. eCollection 2020.

Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets

Affiliations
Review

Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets

Can-Bin Fang et al. Front Cell Dev Biol. .

Abstract

The maintenance of genomic stability is crucial for species survival, and its failure is closely associated with tumorigenesis. The Fanconi anemia (FA) pathway, involving 22 identified genes, plays a central role in repairing DNA interstrand cross-links. Importantly, a germline defect in any of these genes can cause Fanconi's anemia, a heterogeneous genetic disorder, characterized by congenital growth abnormalities, bone marrow failure, and predisposition to cancer. On the other hand, the breast cancer susceptibility genes, BRCA1 and BRCA2, also known as FANCS and FANCD1, respectively, are involved in the FA pathway; hence, researchers have studied the association between the FA pathway and cancer predisposition. Here, we mainly focused on and systematically reviewed the clinical and mechanistic implications of the predisposition of individuals with abnormalities in the FA pathway to cancer, especially breast cancer.

Keywords: Fanconi anemia; SNP; breast cancer; predisposition; susceptibility.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
The schematic elucidation of the FA pathway mechanism used during DNA repair. In response to exogenous and/or endogenous damage, 8 FA genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM) were assembled into the FA core complex, which functioned as a nuclear E3 ubiquitin ligase complex, to monoubiquitinate the I-D heterodimer. The monoubiquitinated I-D heterodimer was localized to the damaged chromatin, and interacted with DNA-repair proteins and other FA proteins (FANCD1, FANCDN, FANCJ, and FANCS) in the FA pathway, to conduct the repair process through homologous recombination (HR). After the damage was repaired, monoubiquitin was removed from the I-D complex by a de-ubiquitylation enzyme, Ubiquitin Specific Peptidase 1 (USP1), to “turn off” the network.
FIGURE 2
FIGURE 2
The mechanisms of tumorigenesis attributable to FA mutations. FA genes maintain genomic integrity through the different phases of the cell cycle, by participating in the DDR process, replication fork protection, normal centrosome function, and spindle assembly checkpoints. Mutations on different FA genes are involved in different mechanisms during the cell cycle, causing genomic instability, and causing a predisposition to cancer.
FIGURE 3
FIGURE 3
Functional domains of BRCA1/2 protein with pathogenic mutations. (A) The functional domains of the BRCA1 protein, mainly containing the RING-finger, SQ-cluster, and BRCT (middle) domains, functionally interacted with BARD1, RAD51C, and ATM (beneath), to orchestrate homologous recombination. The selected reported pathogenic mutations are indicated with black arrows, as shown. (B) BRCA2 was represented by a similar schematic figure with different functional domains (middle) and binding partners (beneath); confirmed pathogenic mutations are also shown above.

References

    1. Abdul-Sater Z., Cerabona D., Potchanant E. S., Sun Z., Enzor R., He Y., et al. (2015). FANCA safeguards interphase and mitosis during hematopoiesis in vivo. Exp. Hematol. 43 1031–1046. 10.1016/j.exphem.2015.08.013 - DOI - PMC - PubMed
    1. Antoniou A. C., Casadei S., Heikkinen T., Barrowdale D., Pylkas K., Roberts J. (2014). Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371 497–506. 10.1056/NEJMoa1400382 - DOI - PMC - PubMed
    1. Antoniou A. C., Pharoah P. D., Mcmullan G., Day N. E., Ponder B. A., Easton D. (2001). Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol. 21 1–18. - PubMed
    1. Apostolou P., Papasotiriou I. (2017). Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med. Press) 9 331–335. 10.2147/BCTT.S111394 - DOI - PMC - PubMed
    1. Ashworth A., Lord C. J. (2018). Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15 564–576. 10.1038/s41571-018-0055-6 - DOI - PubMed